PCI Biotech: Second quarter and first half year 2016 results

Oslo, 30 August 2016.

Please find enclosed the financial report and presentation for second quarter
2016.

Highlights
* Granted Orphan Drug Designation of fimaporfin for treatment of bile duct
cancer in EU
* Commissioned independent expert evaluation of the early promising response
data - results expected Q3 2016
* Lancet Oncology publication of the fimaporfin (Amphinex) first-in-man phase
I study - with independent expert commentary
* fimaVacc ready for clinical validation - a major milestone towards potential
commercialization
* Initiated first research collaboration with commercial entity for fimaVacc

A presentation will be held today, Tuesday 30 August 2016, at Oslo Cancer
Cluster Innovation Park.

Time: Tuesday August 30 2016, 09.00-10.00 hrs.
Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster
Innovation Park, Ullernchausséen 64, Oslo.

Kind regards,
Per Walday
CEO
Email: pw@pcibiotech.no
Mobil: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.